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Purpose:  To  evaluate  the  association  between  clinical  parameters  and  the  diagnosis  of  progres-
sion using  VFI  (Visual  Field  Index)  and  AGIS  (Advanced  Glaucoma  Intervention  Study)  score  in
primary open  angle  glaucoma.
Methods:  Retrospective  study  of  517  visual  ﬁelds  of  78  eyes  with  primary  open  angle  glaucoma
analyzed with  VFI  and  AGIS  score.  Clinical  data  registered  included:  age,  sphere,  pachimetry,
basal intraocular  pressure  (IOP),  and  IOP  during  the  follow  up.
Results:  Only  the  AGIS  score  diagnosis  of  progression  was  associated  with  the  clinical  parame-
ters registered.  Among  the  analyzed  data,  the  mean  IOP  during  follow  up  (p  =  0.0005)  and  IOP
at the  third  month  of  follow  up  (p  =  0.004)  were  statistically  associated  with  progression  using
the AGIS  criteria.
Conclusion:  The  diagnosis  of  perimetric  progression  using  the  AGIS  score  in  the  current  study
was closer  to  the  real  functional  progression  than  the  diagnosis  using  the  VFI,  as  the  former
was associated  with  known  risk  factors  for  progression  in  glaucoma.
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Progresión  del  campo
visual
Progresión  perimétrica  utilizando  el  índice  del  campo  visual  y  la  puntuación  del
estudio  de  intervención  del  glaucoma  avanzado,  y  sus  correlaciones  clínicas
Resumen
Objetivo:  Evaluar  la  asociación  entre  los  parámetros  clínicos  y  el  diagnóstico  de  progresión
utilizando  el  Índice  del  Campo  Visual  (VFI)  y  la  Puntuación  del  Estudio  de  Intervención  del
Glaucoma  en  el  glaucoma  primario  de  ángulo  abierto.
Métodos:  Estudio  retrospectivo  de  517  campos  visuales  de  78  ojos  con  glaucoma  primario  de
ángulo abierto  analizados  con  VFI  y  la  puntuación  AGIS.  Los  datos  clínicos  registrados  incluyeron:
edad, esfera,  paquimetría,  presión  intraocular  (PIO)  basal  y  PIO  durante  el  seguimiento.
Resultados:  Únicamente  el  diagnóstico  de  la  progresión  de  la  puntuación  AGIS  se  asoció  a  los
parámetros  clínicos  evaluados.  Entre  los  datos  analizados,  la  PIO  media  durante  el  seguimiento
(p =  0,0005)  y  la  PIO  al  tercer  mes  de  seguimiento  (p  =  0,004)  se  asociaron  estadísticamente  a
la progresión,  utilizando  los  criterios  AGIS.
Conclusión:  El  diagnóstico  de  la  progresión  perimétrica  utilizando  la  puntuación  AGIS  en  el
estudio actual  se  acercó  más  a  la  progresión  funcional  real  que  el  diagnóstico  utilizando  el  VFI,
ya que  la  primera  se  asoció  a  los  factores  de  riesgo  conocidos  para  la  progresión  del  glaucoma.































Glaucoma  is  a  progressive  disease  in  which  optic  nerve
damage  may  increase  in  certain  patients  despite  adequate
treatment.1 Several  strategies  are  used  to  detect  visual  ﬁeld
(VF)  damage  progression:  clinical  judgment,  event  analysis,
trend  analysis,  and  defect  classiﬁcation  systems.
Brusini  and  Johnson2 established  the  features  of  the  ideal
system  for  VF  progression  detection,  i.e.,  it  should  be  stan-
dardized,  objective,  reproducible,  user  friendly,  supported
by  scientiﬁc  and  clinical  evidence,  able  to  analyze  data
obtained  from  different  models  of  perimeters,  provide  use-
ful  information  on  the  characteristics  of  the  VF  defects,
provide  a  classiﬁcation  consistent  with  structural  damage
data,  widely  used  and  accepted,  able  to  monitor  even  rel-
atively  small  changes  in  functional  loss  over  time,  and
available  on  computer  software  for  easy  day-to-day  clin-
ical  use.  No  currently  available  systems  fulﬁll  all  these
criteria.
There  is  no  gold  standard  for  glaucomatous  functional
worsening  detection  that  can  be  used  to  test  the  differ-
ent  methods  currently  available  to  detect  glaucomatous
progression.3,4 Thus,  if  we  diagnose  perimetric  progression
in  an  eye  using  certain  method,  absence  of  progression  may
be  evident  in  the  same  eye  using  another  method,  and
we  simply  cannot  state  which  of  both  methods  is  correct.5
As  in  any  other  ﬁeld,  the  lack  of  an  accurate  method  to
detect  VF  progression  has  led  to  the  development  of  several
methods.5,6 Unfortunately,  we  do  not  have  adequate  knowl-
edge  of  the  ability  of  each  of  them  to  provide  useful  clinical
information.4
Most  published  studies  that  have  analyzed  the  ability  to
detect  VF  progression  arbitrarily  chose  one  of  the  available
methods  to  detect  VF  progression  against  which  the  new
methods  were  compared.3
Ernest  et  al.4 proposed  a  new  approach  to  identify




ﬁtandard.  They  stated  that  the  detection  method  that  diag-
oses  progression  in  eyes  with  more,  well-known  glaucoma
rogression  risk  factors  is  the  one  nearer  to  the  gold  standard
n  perimetric  progression  detection.
The  Advanced  Glaucoma  Intervention  Study  (AGIS)  score
s  one  of  the  most  speciﬁc  perimetric  progression  diagnostic
ethods  that  has  been  reported.7,8 The  Visual  Field  Index
VFI)  is  an  automated  method  for  detecting  perimetric  pro-
ression  designed  for  the  Humphrey  visual  ﬁeld  (Humphrey
isual  Fields,  Carl  Zeiss  Inc.,  Dublin,  CA,  USA),  which  has
een  described  elsewhere.9 The  VFI  calculates  the  rate
f  perimetric  progression,  which  is  a  useful  parameter  for
laucoma  management,  according  to  the  more  recent  rec-
mmendations  for  glaucoma  follow-up.1,6 To  the  best  of
ur  knowledge,  no  studies  have  compared  the  perimetric
ehavior  of  both  systems  and  their  correlation  with  clinical
arameters,  including  those  considered  to  be  risk  factors  for
laucoma  progression.
aterials and methods
atients  with  open-angle  glaucoma  under  treatment  attend-
ng  the  Glaucoma  and  Neuro-Ophthalmology  Unit  of  the
ospital  Universitario  Príncipe  de  Asturias  (Alcalá  de
enares,  Madrid,  Spain)  between  January  and  May  2012
ere  studied  retrospectively.  All  patients  had  a  diagnosis
f  glaucoma  based  on  the  appearance  of  the  optic  disc  and
eproducible  perimetric  defects  characteristic  of  glaucoma,
t  least  four  years  of  follow-up  and  ﬁve  VFs  obtained  with
 Humphrey  Visual  Field  Analyzer  II  745  (Carl  Zeiss  Inc.,
ublin,  CA,  USA).
Patients  were  excluded  if  they  had  a  visual  acuity
VA)  below  20/40,  any  concomitant  pathology  that  could
lter  VF  measurements,  refractive  errors  over  5.0  diopters
r  3.0  diopters  of  astigmatism  and  false  positives,  false
egatives,  and  ﬁxation  errors  over  25%  in  their  visual
elds.















































Table  1  Basal  clinical  data  of  our  population.
Parameter  Mean  ±  standard  deviation
Age  (years)  70.35  ±  8.77
Sphere  (diopters)  −0.61  ±  2.95
Cylinder  (diopters) −0.59 ±  1.04
Axis (degrees)  92.12  ±  46.55
Pachymetry  (microns)  541.97  ±  36.77
Basal IOP  (mmHg)  24  ±  6.37























sion  using  the  VFI.  The  perimetric  characteristics  of  those
eyes  diagnosed  by  VFI  with  perimetric  progression  compared
with  those  without  progression  are  summarized  in  Table  3.
Table  2  Basal  perimetric  data  of  the  study  population.
Parameter  Mean  ±  standard
deviation
Range
Basal  VFI  (%)  73.79  ±  23.74  14--98
Basal MD  (dB)  −9.98  ±  7.41  −27.88  to  0.09
Basal PSD  (dB)  7.27  ±  4.18  1.83--16.88
Basal AGIS  7.29  ±  5.82  0--1934  
The  study  was  performed  in  accordance  with  the  1964
eclaration  of  Helsinki,  and  the  institutional  review  board
pproved  the  study.
The  VFs  obtained  were  Swedish  Interactive  Threshold
lgorithm  standard  24-2  VFs  with  size  III  stimulus  in  the
umphrey  Visual  Field  Analyzer  Model  745.
From  each  VF,  we  obtained  the  date,  results  of  glaucoma
emiﬁeld  testing,  VFI,  mean  defect  (MD)  and  its  P  value,
attern  standard  deviation  (PSD),  ﬁxation  losses,  false  neg-
tives,  false  positives,  and  glaucoma  progression  analysis
GPA)  alert.  All  VFs  collected  were  analyzed  using  the  VFI
nd  the  AGIS  score.
isual  Field  Index
engtsson  and  Heijl9 described  the  VFI,  which  is  calculated
utomatically  from  the  pattern  deviation  map  values,  is  cal-
ulated  in  such  a  way  that  the  central  points  of  the  VF  have
ore  impact  on  this  global  index  than  the  peripheral  points.
The  VFI  was  calculated  for  each  VF  and  had  a  value  that
anged  from  100%  for  a  normal  VF  to  0%  for  a  completely
bolished  VF.  In  addition,  the  GPAII  analysis  software  calcu-
ates  the  linear  regression  of  all  VFI  values  from  the  same
ye  and  provides  the  estimated  change  in  the  VFI  expected
or  the  next  three  to  ﬁve  years.  The  results  are  shown  on  a
FI  diagram  and  a  VFI  bar  graph.  We  considered  that  eyes
ad  perimetric  progression  when  the  VFI  progression  rate
as  statistically  signiﬁcant.
The  VFI-related  information  collected  in  the  current
tudy  was  the  annual  percentage  decrease  in  VFI,  its
tandard  deviation,  and  its  P  value.
GIS  score
he  AGIS  score,10 developed  to  detect  perimetric  pro-
ression  during  the  Advanced  Glaucoma  Intervention  Study
AGIS),  is  based  on  the  analysis  of  the  24-2  area  of  the  VF
ubdivided  into  three  areas:  nasal,  superior,  and  inferior.
he  scores  for  each  of  these  areas  are  calculated  from  the
otal  deviation  map  values  and,  depending  on  the  location,
he  decibel  loss  that  is  considered  abnormal  ranges  from  5
o  9.  The  score  for  each  VF  ranges  from  0  (no  VF  damage)  to
0  (terminal  glaucoma).  Perimetric  progression  is  diagnosed
hen  an  increase  in  the  AGIS  score  of  four  or  more  points  is
etected  in  three  successive  VF  measurements.
linical  data
e  collected  the  following  data  from  the  medical  records:
he  more  damaged  eye,  age,  gender,  date  when  the  VF
xamination  was  performed,  date  of  the  visit  to  the  ofﬁce,
amily  history  of  glaucoma,  refraction,  pachymetry,  number
f  treatments,  visual  acuity  (VA),  and  intraocular  pressure
IOP).  From  this  raw  data,  we  calculated  the  average  IOP,
ercent  IOP  decrease  every  12  months,  percent  IOP  decrease
etween  the  ﬁrst  and  the  last  IOP  measurements,  and  the
verage  percent  IOP  decrease.IOP: intraocular pressure; VA: visual acuity; dB: decibels; mmHg:
millimeter of mercury.
tatistical  analysis
tatistical  analysis  was  performed  using  Statview
E  +  Graphics  (Abacus  Concepts  Inc.,  Berkeley,  CA)  using  a
acintosh  PowerBook  1400cs/117  (Apple  Computer  Inc.,
upertino,  CA).
We  used  the  Kolmogorov--Smirnov  test  to  evaluate  the
ormality  of  our  data.  The  continuous  variables  adjusted
o  normality  were  expressed  as  the  mean  and  the  standard
eviation.  An  unpaired  t-test  adjusted  by  the  Bonferroni  cor-
ection  for  multiple  comparisons  was  used  to  compare  the
erimetric  and  clinical  data  of  eyes  with  and  without  peri-
etric  progression.  The  level  of  signiﬁcance  was  established
t  P  <  0.05.
esults
e  obtained  517  VFs  from  78  eyes  (42  left  eyes,  36  right
yes)  of  46  patients  (27  males,  58.7%  of  our  sample).
he  same  investigator  (JGO)  analyzed  each  VF  using  the
GIS  score.  The  mean  follow-up  time  was  7.63  ±  2.07  years
range,  4.33--14.67  years).
More  basal  clinical  and  perimetric  data  are  shown  in
ables  1  and  2, respectively.
nalysis  of  perimetric  progression  using  Visual
ield Index  and  correlated  clinical  data  behavior
wenty-nine  eyes  were  diagnosed  with  perimetric  progres-No. of  VFs  6.63  ±  1.49  5--16
VFI: Visual Field Index; MD: mean deviation; PSD: pattern
standard deviation; AGIS: Advanced Glaucoma Intervention
Study; VFs: visual ﬁelds.
Perimetric  progression  using  the  Visual  Field  Index  and  the  Advanced  Glaucoma  Intervention  Study  score  235
Table  3  Perimetric  characteristics  of  eyes  diagnosed  with  VFI  perimetric  progression  compared  with  stable  eyes.
Parameter  Progression  No  progression  P  values
Mean  SE  Mean  SE
Initial  VFI  (%)  76.89  22.4  71.95  24.52  0.3
Initial MD  (dB)  −9.08  6.33  −10.51  7.99  0.4
Initial MSD  (dB) 6.70  3.74  7.59  4.41  0.3
Number of  visual  ﬁelds 6.31 1.36 6.81 2.27  0.2
Initial AGIS 6.96 5.06 7.49 6.29 0.7
Final  MD  (dB) −16.14 7.43 −11.49 7.36 0.008
Final  PSD  (dB)  8.03  3.73  8.38  3.13  0.6
Final AGIS  8.12  6.09  12.10  4.84  0.003















pSE: standard deviation; VFI: Visual Field Index; MD: mean devia
Glaucoma Intervention Study; VFs: visual ﬁelds.
The  behavior  of  the  clinical  data  studied  during  the
follow-up  period  and  correlated  with  the  VFI  diagnosis  of
perimetric  progression  is  summarized  in  Table  4.
Analysis  of  perimetric  progression  using  the
Advanced Glaucoma  Intervention  Study  score  and
correlated  clinical  data  behavior
Seventeen  eyes  were  diagnosed  with  perimetric  progression
using  the  AGIS  score.  The  perimetric  characteristics  of  eyes
with  perimetric  progression  compared  with  those  without
progression  are  summarized  in  Table  5.
The  behavior  of  the  clinical  data  studied  during  the
follow-up  period  and  correlated  with  the  AGIS  score  diag-
nosis  of  perimetric  progression  is  summarized  in  Table  6.Discussion
The  diagnosis  of  perimetric  progression  using  the  AGIS  score





Table  4  Clinical  data  from  eyes  diagnosed  with  VFI  perimetric  pr
Parameter  Progres
Mean  
Age  (years)  72.55  
Initial VA  0.77  
Sphere (diopters)  −0.52  
Pachymetry (microns)  542  
Initial IOP  (mmHg)  25  
3-month IOP  (mmHg)  16.92  
% Decrease  in  IOP  at  12  months  of  follow-up  29.14  
Mean %  decrease  in  IOP  31.41  
Standard dev1 12.8  
% Decrease  in  IOP  42.03  
Mean IOP  (mmHg)  16.35  
Standard dev2 3.81  
Final VA  0.72  
IOP: intraocular pressure; VA: visual acuity; SE: standard deviation; 3-
IOP: mean % IOP decrease during follow-up; standard dev1: standard de
in IOP: % IOP decrease from initial to ﬁnal examinations; standard dev2dB: decibels; PSD: pattern standard deviation; AGIS: Advanced
rogression  than  the  diagnosis  of  perimetric  progression
sing  the  VFI,  as  the  former  was  correlated  with  worst  IOP
evels  during  the  follow-up  period.
We  have  evaluated  the  validity  of  two  different  proce-
ures  for  the  diagnosis  of  perimetric  progression  studying
imultaneously  how  clinical  data  behave  during  a  certain
eriod  of  time.
The  validity  of  a  measurement  system  is  deﬁned  as  the
bility  to  measure  the  desired  parameter.11 The  most  com-
on  validity  studies  are  statistical  studies,  with  results
btained  from  the  sensitivity,  speciﬁcity,  odds  ratios,  and
ositive  and  negative  predictive  values.  The  prerequisite
or  those  parameters  calculation  is  the  presence  of  a
old  standard.11 Nevertheless,  there  is  no  gold  standard
mong  the  available  procedures  to  evaluate  perimetric
rogression.4
From  the  clinimetric  point  of  view,  the  validity  can  be
valuated  by  comparison  with  the  clinical  data,  what  is
ermed  ‘‘construct  validity.’’4,11 Some  authors4 believe  that
his  kind  of  study  should  be  conducted  instead  of  studies  that
ompare  different  systems  of  perimetric  progression,  where
ogression  compared  with  stable  eyes.
sion  No  progression  P  value
S.E.  Mean  S.E.
8.27  69.0  6.13  0.08
0.22  0.82  0.23  0.3
3.15  −0.64  2.89  0.8
52.5  541.71  32.93  0.9
6.89  23.40  6.03  0.2
3.16  15.84  4.01  0.2
22.19  29.87  21.11  0.8
17.83  31.14  18.31  0.9
5.79  12.67  6.35  0.9
19  36.89  23.41  0.3
2.59  15.69  1.76  0.1
1.49  3.88  1.28  0.8
0.24  0.71  0.29  0.8
month IOP: IOP at third month of follow-up; mean % decrease in
viation of the mean % IOP decrease during follow-up; % decrease
: standard deviation of the mean IOP values during follow-up.
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Table  5  Perimetric  characteristics  of  eyes  diagnosed  with  AGIS  score  perimetric  progression  compared  with  stable  eyes.
Parameter  Progression  No  Progression  P  value
Mean  SE  Mean  SE
Initial  VFI  (%)  78.94  22.54  72.36  24.04  0.3
Initial MD  (dB)  −8.49  6.70  −10.39  7.59  0.3
Initial PSD  (dB) 6.51  4.24  7.47  4.17  0.4
No. of  VFs 6.70 1.49 6.60 2.12  0.8
Final VFI  (%) 52.0 27.3 66.68 24.57 0.03
Final  MD  (dB) −16.51 7.70 −12.3 7.48 0.04
Final  DSM  (dB)  8.81  3.34  7.98  3.55  0.3































fSE: standard deviation; VFI: Visual Field Index; MD: mean deviatio
ne  system  is  selected  as  the  reference  system  against  which
he  other  detection  methods  are  compared.
The  glaucoma  risk  factors  used  to  evaluate  the  validity  of
he  VFI  and  the  AGIS  score  were  selected  based  on  the  liter-
ture  search.  Regarding  the  IOP,  the  following  parameters
ave  been  deﬁned  as  risk  factors  for  glaucoma  perimet-
ic  progression:  mean  IOP,12,13 IOP  ﬂuctuations14 (standard
eviation  of  the  mean  IOP  in  the  current  study),  and  initial
OP.15 In  addition,  age,13,14 central  corneal  thickness,12 and
yopia16 are  possible  risk  factors  for  glaucoma  progression.
The  AGIS  score  is  probably  one  of  the  most  speciﬁc
ystems  used  to  diagnose  perimetric  progression.  In  addi-
ion  to  the  fact  that  it  was  the  system  used  by  the  AGIS
nvestigators7 to  diagnose  progression,  this  method  has
een  compared  to  other  tools  used  to  evaluate  perimetric
12rogression. Based  on  the  current  results,  the  estimation
f  the  functional  loss  using  the  AGIS  score  was  closer  to  the
ctual  perimetric  progression  than  the  estimation  provided




Table  6  Clinical  data  from  eyes  diagnosed  with  AGIS  score  perim
Parameter  Progression  
Mean  SE  
Age  (years)  71.88  9.2
Initial VA  0.81  0.1
Sphere 0.12  3.2
Pachymetry  (microns)  544.57  26.2
Initial IOP  (mmHg)  26.11  6.0
3-month IOP  (mmHg)  18.71  3.5
% Decrease  in  IOP  at  12  months  31.81  20.5
Mean %  decrease  in  IOP  32.58  13.2
Standard dev1 13.05  5.2
% Decrease  in  IOP  46.05  20.4
Mean IOP  (mmHg)  17.47  2.5
Standard dev2 3.90  1.4
Final VA 0.70  0.2
IOP: intraocular pressure; VA: visual acuity; SE: standard deviation; 3-
IOP: mean % IOP decrease during follow-up; standard dev1: standard de
in IOP: % IOP decrease from initial to ﬁnal examinations; standard devD: pattern standard deviation; dB: decibels; VFs: visual ﬁelds.
When  the  effect  of  the  initial  perimetric  features  on
erimetric  progression  was  studied,  none  of  the  studied
arameters  were  associated  with  progression  with  either  the
FI  or  AGIS  score.
Although  our  sample  differed  from  those  studied  in  large
laucoma  trials,14,17 the  current  results  agree  with  the  Col-
aborative  Normal  Tension  Glaucoma  Study17 and  differ  from
he  results  obtained  in  the  Early  Manifest  Glaucoma  Trial,18
he  Collaborative  Initial  Glaucoma  Treatment  Study,19 and
GIS.14 The  last 14 is  the  only  glaucoma  trial  that  reported
hat  a  better  VF  at  the  beginning  of  the  follow-up  period
as  a  risk  factor  for  progression.  The  same  authors  that
escribed  this  association  have  not  been  able  to  explain  it,
owever,  this  association  disappears  when  other  software
or  perimetric  progression  is  used.  The  authors  proposed
hat  this  fact  was  an  intrinsic  consequence  of  the  AGIS  score
lgorithm.
Compared  with  other  cohorts  studied  with  the  VFI,  Rao
t  al.20 found  an  association  between  the  initial  perimetric
etric  progression  compared  with  stable  eyes.
No  progression  P  value
Mean  SE
2  69.91  8.67  0.4
8  0.80  0.24  0.8
7  −0.84  2.84  0.3
6  541.25  39.35  0.7
3  23.01  6.38  0.1
1  15.57  3.48  0.004
5  29.01  21.71  0.6
6  30.86  18.45  0.7
3  12.52  6.15  0.7
7  36.78  22.39  0.1
8  15.51  1.76  0.0005
2  3.84  1.34  0.9
9  0.73  0.25  0.7
month IOP: IOP at third month of follow-up; mean % decrease in
viation of the mean % IOP decrease during follow-up; % decrease












RPerimetric  progression  using  the  Visual  Field  Index  and  the  A
damage  measured  by  the  MD  and  Pattern  Standard  Devia-
tion  (PSD)  and  the  rate  of  progression  in  the  groups  with
initial  and  advanced  glaucoma  but  not  in  the  group  with
moderate  glaucoma,  in  a  group  with  similar  perimetric  dam-
age  than  our  sample.  Bengtsson  et  al.  also  reported  that
there  was  no  correlation  between  the  initial  VFI  and  the
rate  of  progression,21 although  they  also  found  a  high  cor-
relation  between  the  estimated  and  the  actual  progression
rates.
The  absence  of  substantial  differences  in  the  number  of
VFs  between  patients  with  progressing  glaucoma  and  those
who  are  stable  eliminates  a  possible  confounding  factor  as
Nouri-Mahdavi  et  al.  reported  that  a  higher  number  of  VF
examinations  leads  to  a  higher  rate  of  diagnosis  of  perimet-
ric  progression  mainly  in  trend-based  systems.22
The  diagnosis  of  perimetric  progression  using  the  VFI  is
associated  with  perimetric  damage  at  the  end  of  the  follow-
up  period,  quantiﬁed  by  the  MD  and  the  AGIS  score.  However,
because  the  MD  and  the  diagnosis  of  perimetric  progression
evolved  in  the  same  direction  (i.e.,  the  mean  MD  is  worst  at
the  end  of  the  follow-up  period),  the  AGIS  score  runs  in  the
opposite  direction,  with  those  diagnosed  with  VFI  perimetric
progression  having  a  better  ﬁnal  AGIS  score.
Kimura  et  al.23 studied  the  relationship  between  the  VFI
and  MD  and  found  a  signiﬁcant  correlation  between  both
parameters.  Moreover,  Cho  et  al.24 reported  that  this  corre-
lation  did  not  depend  on  the  level  of  perimetric  damage.
The  diagnosis  of  progression  using  the  AGIS  score  was  sig-
niﬁcantly  associated  in  the  current  study  with  the  perimetric
parameters  at  the  end  of  the  follow-up  period  (ﬁnal  VFI,  ﬁnal
MD,  and  percent  decrease  in  VFI/year),  excluding  the  PSD.
We  did  not  found  any  study  that  evaluated  the  correlation
between  the  diagnosis  of  perimetric  progression  using  both
the  AGIS  score  and  VFI  in  the  same  group  of  patients.
Regarding  the  results  of  the  current  study,  with  the  VFI
diagnosis  of  progression  running  in  the  opposite  direction  of
the  ﬁnal  AGIS  score  and  the  AGIS  Score  diagnosis  of  perimet-
ric  progression  associated  with  most  of  the  ﬁnal  perimetric
parameters  (including  the  VFI  rate),  it  is  plausible  that  both
systems  measure  slightly  different  things.  Another  hypoth-
esis  for  the  origin  of  this  divergence  might  be  caused  by
an  inadequate  design  of  the  algorithm  for  the  statistical
signiﬁcance  of  the  VFI  trend.  The  VFI  rate  statistical  signif-
icance  is  estimated  in  a  mathematical  way,  in  other  words,
using  a  95%  conﬁdence  interval  (CI)  of  the  linear  regression
of  the  available  VFs.9 Some  authors5 proposed  the  addition
of  the  CI  when  obtaining  rates  of  progression  of  perimet-
ric  damage,  a  recommendation  that  has  been  followed  by
the  designers  of  the  VFI.  We  believe  as  others  do25 that
this  might  be  inadequate,  and  that  the  VFI  software  lacks
a  database  of  normal  VFI  loss  per  year  against  which  the
rates  of  progression  obtained  should  be  compared  to  ﬂag
them  as  pathological.
Our  results  are  limited  mainly  by  two  reasons:  the  low
number  of  patients  enrolled  and  also  by  the  difﬁculties  in
using  the  AGIS  Score  in  a  clinical  environment  as  its  calcula-
tion  is  certainly  time  consuming  and  may  be  useful  only  for
research  purposes.In  conclusion,  in  the  current  study,  the  diagnosis  of  peri-
metric  progression  using  the  AGIS  score  is  nearer  to  the
actual  functional  progression  than  the  diagnosis  of  perimet-
ric  progression  using  the  VFI.  Nevertheless,  more  studies  arenced  Glaucoma  Intervention  Study  score  237
eeded  to  increase  the  level  of  certainty  when  diagnosing
laucomatous  progression.
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